Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952655 | 0.89 | MAPT (0.42) | CNR2RAB9ANPC1KMT2AALDH1A1 | |
| SCHEMBL18952675 | 0.80 | MAPT (0.43) | RAB9ANPC1KMT2AALDH1A1MAPT | |
| SCHEMBL18952523 | 0.74 | CYP1A2 (0.42) | CNR2ALDH1A1KDM4EPOLB | |
| SCHEMBL18952606 | 0.70 | MAPT (0.39) | CNR2RAB9ANPC1KMT2AALDH1A1 | |
| SCHEMBL18952603 | 0.69 | SCN9A (0.40) | KMT2AALDH1A1MAPTMEN1KDM4E | |
| SCHEMBL18971479 | 0.68 | SCN9A (0.33) | CNR2RAB9ANPC1SCN9A | |
| SCHEMBL18952565 | 0.68 | MAPT (0.39) | CNR2RAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL4063342 | 0.67 | MAPT (0.44) | RAB9ANPC1KMT2AALDH1A1MAPT | |
| SCHEMBL18952532 | 0.66 | NPC1 (0.58) | RAB9ANPC1KMT2AALDH1A1MAPT | |
| SCHEMBL18971279 | 0.66 | ALDH1A1 (0.40) | KMT2AALDH1A1MAPTMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386978-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | CNR2 281/4885RAB9A 1413/4885NPC1 440/4885 |
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | CNR2 281/4885RAB9A 1413/4885NPC1 440/4885 |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | CNR2 281/4885RAB9A 1413/4885NPC1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.